Four expert-led educational events with Allergan Medical Institute (AMI), Science of AgingTM and Allergan Aesthetics (AA) Global Medical Affairs AMI symposia will focus on a new Allergan Aesthetics (AA) Signature Program and celebrate 10 years […]
Tag: AbbVie
ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) Data presented […]
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib in adults with giant cell arteritis (GCA)1 The primary endpoint of sustained remission* and key […]
AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results
Reports Full-Year Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $1.52 Per Share […]
Allergan Aesthetics launches new AA Signature Program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans
AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes NORTH CHICAGO, Ill., Jan. 29, 2025 /PRNewswire/ — In response to growing demand for personalized, patient-centric aesthetic solutions1,2, Allergan Aesthetics, an AbbVie […]
